These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31843464)

  • 1. Small molecules targeting HIF-1α pathway for cancer therapy in recent years.
    Tang W; Zhao G
    Bioorg Med Chem; 2020 Jan; 28(2):115235. PubMed ID: 31843464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in inhibition of protein-protein interactions targeting hypoxia-inducible factor-1 for cancer therapy.
    Li J; Xi W; Li X; Sun H; Li Y
    Bioorg Med Chem; 2019 Apr; 27(7):1145-1158. PubMed ID: 30819620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
    Xia Y; Choi HK; Lee K
    Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural products as potent inhibitors of hypoxia-inducible factor-1α in cancer therapy.
    Zhong JC; Li XB; Lyu WY; Ye WC; Zhang DM
    Chin J Nat Med; 2020 Sep; 18(9):696-703. PubMed ID: 32928513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dictamnine promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, invasion and proliferation by downregulating the HIF-1α and Slug signaling pathways.
    Wang JY; Wang Z; Li MY; Zhang Z; Mi C; Zuo HX; Xing Y; Wu YL; Lian LH; Xu GH; Piao LX; Ma J; Jin X
    Chem Biol Interact; 2018 Dec; 296():134-144. PubMed ID: 30266538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KNK437, abrogates hypoxia-induced radioresistance by dual targeting of the AKT and HIF-1α survival pathways.
    Oommen D; Prise KM
    Biochem Biophys Res Commun; 2012 May; 421(3):538-43. PubMed ID: 22521642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical biology approach for the development of hypoxia inducible factor (HIF) inhibitor LW6 as a potential anticancer agent.
    Naik R; Han S; Lee K
    Arch Pharm Res; 2015 Sep; 38(9):1563-74. PubMed ID: 26310207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents.
    Wei J; Yang Y; Lu M; Lei Y; Xu L; Jiang Z; Xu X; Guo X; Zhang X; Sun H; You Q
    Mini Rev Med Chem; 2018; 18(4):296-309. PubMed ID: 27484627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, Binding Affinity Analysis, and
    Dawn Woodfield J; Bhardwaj A; Bergman C; Wuest F
    ChemMedChem; 2022 Jan; 17(1):e202100544. PubMed ID: 34595843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of hypoxia-inducible factor-1alpha as a cancer therapy target.
    Patiar S; Harris AL
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S61-75. PubMed ID: 17259560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.
    Yu T; Tang B; Sun X
    Yonsei Med J; 2017 May; 58(3):489-496. PubMed ID: 28332352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel small molecule HIF-1alpha translation inhibitor.
    Narita T; Yin S; Gelin CF; Moreno CS; Yepes M; Nicolaou KC; Van Meir EG
    Clin Cancer Res; 2009 Oct; 15(19):6128-36. PubMed ID: 19789328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factor-1 as a therapeutic target in cancer.
    Tang CM; Yu J
    J Gastroenterol Hepatol; 2013 Mar; 28(3):401-5. PubMed ID: 23173651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
    Godse P; Kumar P; Yewalkar N; Deore V; Lohar M; Mundada R; Padgaonkar A; Manohar S; Joshi A; Bhatia D; Desai N; Damre A; Bhonde M; Joshi K; Sharma R; Kumar S
    Anticancer Agents Med Chem; 2013 Nov; 13(9):1460-6. PubMed ID: 24102269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer.
    Ajith TA
    J Basic Clin Physiol Pharmacol; 2018 Dec; 30(1):11-18. PubMed ID: 30260792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent agents targeting HIF-1α for cancer therapy.
    Hu Y; Liu J; Huang H
    J Cell Biochem; 2013 Mar; 114(3):498-509. PubMed ID: 22961911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor.
    Lee K; Kim HM
    Arch Pharm Res; 2011 Oct; 34(10):1583-5. PubMed ID: 22076756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting hypoxia-inducible factor 1 for cancer therapy.
    Melillo G
    Mol Cancer Res; 2006 Sep; 4(9):601-5. PubMed ID: 16940159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.